All ROIV Content

Roivant Sciences (ROIV) Sec Form 8K

Roivant Sciences (NASDAQ: ROIV) Sec Form 8K

April 3, 20261 min read

Roivant Sciences (ROIV) Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release

April 2, 20261 min read

Roivant Sciences (ROIV) Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release

April 2, 20261 min read

Roivant Sciences (ROIV) New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release

March 29, 20261 min read

Roivant Sciences (ROIV) Q2 2026 Earnings Call Transcript

Roivant Sciences (NASDAQ: ROIV) Q2 2026 Earnings Call dated Feb. 06, 2026 Corporate Participants: Stephanie Lee Griffin — Chief Operating...

March 10, 202649 min read

Roivant Sciences (ROIV) Sec Form 8K

Roivant Sciences (NASDAQ: ROIV) Sec Form 8K

March 5, 20261 min read

Roivant Sciences (ROIV) Sec Form 8K

Roivant Sciences (NASDAQ: ROIV) Sec Form 8K

March 5, 20261 min read

Roivant Sciences (ROIV) Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release

March 3, 20261 min read

Roivant Sciences (ROIV) Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release

March 3, 20261 min read

Roivant Sciences (ROIV) Sec Form 10Q

Roivant Sciences (NASDAQ: ROIV) Sec Form 10Q

February 7, 20261 min read